Bengaluru: US regulator nod for Jubilant’s anti-infection drug  

Bengaluru, June 23 (IANS) Leading Indian drug maker Jubilant Life Sciences Tuesday announced it had received approval of the US Food and Drug Administration (FDA) for its tablets used in treating adults for various infections, including pneumonia.

“Levofloxacin tablets are the generic version of Levaquin of Ortho-McNeil, used for treating infections such as pneumonia, sinusitis, bronchitis, prostatitis, urinary tract and inhalational anthrax,” the Noida-based firm said in a statement here.

According to IMS Health, the market size for Levofloxacin tablets is estimated to be $28 million (Rs.179 crore) per annum.

The company, which had 806 filings for formulations till March 31, got approval for 368 of them from various regions worldwide, including 72 from FDA.

As an integrated drug maker, Jubilant manufactures and supplies active pharmaceutical ingredients, solid dosage formulations, specialty pharmaceuticals and life science ingredients. The company also provides services in contract manufacturing and drug discovery solutions to global firms from its 10 production units in India, Canada and the US.


Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of or any employee thereof. is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here